Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.-Reference-Cited by-同舟云学术

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:1018-1018
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sharma Priyanka¹,Abramson Vandana Gupta²,O'Dea Anne³,Pathak Harsh B⁴,Pessetto Ziyan Y.¹,Wang Yen Y.⁴,Finke Karissa⁴,Hoffmann Marc Steven⁴,Elia Manana⁵,Lewis Sharon⁶,Scott Jecinta⁴,De Jong Jilliann⁷,Urban Julia⁴,Heldstab Jaimie⁴,LaFaver Stephanie⁴,Williamson Stephen K.⁸,Reed Greg⁹,Kimler Bruce F.⁴,Khan Qamar J.¹,Godwin Andrew K.¹

Affiliation:

1. University of Kansas Medical Center, Kansas City, KS;

2. Vanderbilt University, Nashville, TN;

3. Kansas University Medical Center, Westwood, KS;

4. University of Kansas Medical Center, Westwood, KS;

5. University of Kansas Cancer Center, Mission Hill, KS;

6. University of Kansas Clinical Research Center, Fairway, KS;

7. University of Kansas Medical Center, Fairway, KS;

8. University of Kansas Cancer Center, Kansas City, KS;

9. University of Kansas, Kansas City, KS;

Publisher

American Society of Clinical Oncology (ASCO)